Eupraxia Pharmaceuticals Inc.
EPRX
$3.27
-$0.0092-0.28%
| Weiss Ratings | EPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | EPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | EPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.53 | |||
| Price History | EPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -10.16% | |||
| 30-Day Total Return | -2.68% | |||
| 60-Day Total Return | 5.35% | |||
| 90-Day Total Return | 0.31% | |||
| Year to Date Total Return | 4.47% | |||
| 1-Year Total Return | 7.57% | |||
| 2-Year Total Return | 11.22% | |||
| 3-Year Total Return | 42.17% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -26.80% | |||
| 52-Week Low % Change | 49.05% | |||
| Price | EPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $4.48 | |||
| 52-Week Low Price | $2.20 | |||
| 52-Week Low Price (Date) | Oct 14, 2024 | |||
| 52-Week High Price (Date) | Feb 27, 2025 | |||
| Valuation | EPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 117.22M | |||
| Enterprise Value | 114.33M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.99 | |||
| Earnings Per Share Growth | -15.34% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 68.75 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $3.27 | |||
| Enterprise Value/EBITDA (TTM) | -3.34 | |||
| Enterprise Value/EBIT | -4.23 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | EPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 35.64M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | EPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 250 590 3968 | |||
| Address | 2067 Cadboro Bay Road Victoria, BC V8R 5G4 | |||
| Website | www.eupraxiapharma.com | |||
| Country | Canada | |||
| Year Founded | 2011 | |||
| Profitability | EPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | EPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -61.14% | |||
| Return on Equity | -- | |||
| Income Statement | EPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -34.27M | |||
| EBIT (TTM) | -27.00M | |||
| Net Income (TTM) | -25.50M | |||
| Net Income Avl. to Common (TTM) | -25.50M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 28.99% | |||
| EPS Diluted (TTM) | -0.99 | |||
| EPS Diluted Growth (Q YOY) | -17.84% | |||
| Balance Sheet | EPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 33.10M | |||
| Cash Per Share (Q) | $0.93 | |||
| Total Current Assets (Q) | 34.44M | |||
| Total Preferred Equity (Q) | 31.71 | |||
| Total Equity (Q) | 31.84M | |||
| Current Ratio (Q) | 11.096 | |||
| Book Value Per Share (Q) | $0.05 | |||
| Total Assets (Q) | 34.94M | |||
| Total Current Liabilities (Q) | 3.10M | |||
| Total Debt (Q) | 71.90K | |||
| Total Liabilities (Q) | 3.10M | |||
| Total Common Equity (Q) | 1.70M | |||
| Cash Flow | EPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -75.20K | |||
| Cash from Financing (TTM) | 45.78M | |||
| Net Change in Cash (TTM) | 13.76M | |||
| Levered Free Cash Flow (TTM) | -27.40M | |||
| Cash from Operations (TTM) | -29.99M | |||
